Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Segue Study: Switching from Xyrem to XYWAV in Narcolepsy
NCT04794491Phase 4Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in narcolepsy, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change in Weekly Rate of Cataplexy Attacks at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04794491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794491.